#PubsaludMurcia Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer...l. https://t.co/MrkoPMWhPn
1,892 followers
2,357 followers
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART):an open-label,single https://t.co/G2vItLQlLF #hvhebron #onco #S
8,456 followers
neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2+ #BreastCancer - Opti-HER HEART trial Cardiac AE : 2.4% pCR: upto 80% (HER2-E) https://t.co/5YyYAqPUF2
50 followers
RT @prat_aleix: The results of our @_SOLTI Opti-HER HEART HER2+ neoadjuvant breast cancer trial are out in @BMCMedicine -- PAM50 HER2-enric…